
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone978-671-8001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$343.37 million
Profitability
Miscellaneous
Employees488
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) issued its earnings results on Thursday, October, 31st. The medical equipment provider reported $0.28 EPS for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to analyst estimates of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The company's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the company posted $0.24 earnings per share. View Lantheus' Earnings History.
When is Lantheus' next earnings date?
What guidance has Lantheus issued on next quarter's earnings?
Lantheus updated its fourth quarter earnings guidance on Thursday, October, 31st. The company provided EPS guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million.
What is the consensus analysts' recommendation for Lantheus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.
Has Lantheus been receiving favorable news coverage?
Media headlines about LNTH stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Lantheus.
Are investors shorting Lantheus?
Lantheus saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 1,210,000 shares, a decrease of 9.7% from the October 31st total of 1,340,000 shares. Based on an average daily volume of 411,400 shares, the days-to-cover ratio is presently 2.9 days. Approximately 3.2% of the company's shares are short sold. View Lantheus' Current Options Chain.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Heska (HSKA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO) and GeneNews (GNWSF).
What other stocks do shareholders of Lantheus own?
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
- Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
- Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
- Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
- Mr. John J. Bolla, Chief Operating Officer (Age 49)
When did Lantheus IPO?
(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.76%), Vaughan Nelson Investment Management L.P. (3.49%), Tamarack Advisers LP (1.91%), Voya Investment Management LLC (1.68%), Rice Hall James & Associates LLC (1.09%) and Peregrine Capital Management LLC (0.56%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.
Which major investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vaughan Nelson Investment Management L.P., Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC, Cadence Capital Management LLC, Hancock Whitney Corp, State Street Corp and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.
Which major investors are buying Lantheus stock?
LNTH stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Rice Hall James & Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Tealwood Asset Management Inc., Hussman Strategic Advisors Inc., Chicago Equity Partners LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Lantheus.
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $20.63.
How big of a company is Lantheus?
Lantheus has a market capitalization of $809.69 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.
What is Lantheus' official website?
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.